At a glance
ClinicalIndex Comparison RecordN/ACompleted· 755 enrolled
Drug / intervention
Ropiniroledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-centre, Observational, Post-marketing Surveillance to Monitor the Safety of REQUIP(Ropinirole) Administered in Korean Restless Leg Syndrome Patients According to the Prescribing Information
In Brief
An observational study evaluating Ropinirole for Restless Legs Syndrome. Completed, enrolled 755 participants.
Detailed Summary
post-marketing surveillance to monitor safety and efficacy of ropinirole during using of treatment for RLS
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRestless Legs Syndrome
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
Primary CompletionNov 2009
First PostedApr 2011
TodayJul 2026
First PostedApr 1, 2011
Enrollment StartApr 1, 2006
Primary CompletionNov 30, 2009
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 15.3 years ago
Interventions
Ropiniroledrug
Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.